Medicine. A portfolio model of drug development for tuberculosis.
Explore the source record for details and available documents.
Antitubercular Agents↗
Biomedical subjects
Carol Dukes Hamilton
Publications and source records attributed to Carol Dukes Hamilton.
Racial and ethnic disparities in pediatric tuberculosis in North Carolina.
OBJECTIVES: To investigate an increase in active pediatric tuberculosis (TB) cases in North Carolina from 9 cases in 2001 to 32 cases in 2002, and to pilot test a screening tool for detection of latent TB infection in children. DESIGN: Retrospective cohort and cross-sectional study. SETTING: State of North Carolina and a county public health department pediatric clinic. PARTICIPANTS: Children younger than 15 years with TB in North Carolina from January 1, 1994, to December 31, 2002, and children younger than 21 years initially seen in a primary care public health department pediatric clinic from July 16, 2004, to December 8, 2004. INTERVENTIONS: We reviewed medical records for 180 children (<15 years) with active TB reported in North Carolina. We subsequently initiated a screening project at a county public health department pediatric clinic. MAIN OUTCOME MEASURES: Incidence of TB and prevalence of latent TB infection. RESULTS: One hundred eighty pediatric TB cases were reported from 1994 to 2002. Compared with 0.2 case per 100 000 non-Hispanic white children, the incidence rates were 3.0 cases per 100 000 non-Hispanic black children (P = .003) and 4.5 cases per 100 000 Hispanic children (P = .01); 88.3% of pediatric patients with TB were nonwhite. The screening project detected 2 cases of latent TB infection among 864 US-born children of foreign-born parents. CONCLUSIONS: The burden of pediatric TB is almost entirely borne by black and Hispanic children in North Carolina. Tuberculin skin testing of US-born children of foreign-born parents is of low yield; more efficient screening strategies are necessary.
Adolescent↗
Current issues in global tuberculosis control.
Despite attempts to standardize tuberculosis (TB) control strategies, there remains wide variation in the selection and implementation of control strategies within and among nations. Some of this variation is appropriate; based on wide variations in the available resources, the prevalence of TB infection, the incidence of TB disease, the relative contribution of reactivation versus recent transmission to incident cases, and the rate of HIV co-infection. This review will discuss three controversial questions relevant to global TB control: (1) What is the role of the treatment of latent TB infection in global TB control? (2) What are successful strategies to control immigrant TB in low incidence countries? (3) What are successful strategies to control TB in persons with HIV infection?
Antitubercular Agents↗
Immunosuppression related to collagen-vascular disease or its treatment.
Collagen-vascular diseases are associated with immune dysregulation and inflammation, leading to tissue destruction or compromise. Immunosuppression is more commonly associated with the drugs used to treat these disorders than with the diseases themselves. The newest agents being used to treat collagen-vascular diseases are the tumor necrosis factor (TNF)-alpha inhibitors. U.S. Food and Drug Administration-approved TNF-alpha inhibitors have differing effects on the immune system, reflecting their potency and mechanisms of action. They are particularly effective in breaking down granulomatous inflammation, which makes them effective treatment for sarcoidosis and Wegener's granulomatosis. This same property makes them likely to break down the host defense mechanism that normally contains pathogens such as mycobacteria and fungi in a dormant state, namely the physical and immunologic barrier formed by granulomas in the lung and elsewhere. The most common infection reported with the TNF-alpha inhibitors has been tuberculosis, which may manifest as pulmonary and/or extrapulmonary disease, with the latter being more common and severe than usual. Histoplasma capsulatum, Aspergillus, Cryptococcus neoformans, and Listeria monocytogenes have also been described in a number of cases, and their frequency is discussed.
Collagen Diseases↗
Infectious complications of treatment with biologic agents.
PURPOSE OF REVIEW: There are three tumor necrosis factor-alpha inhibitors on the US and European markets today, and uncommon but devastating infectious complications accompany their use. This review describes the most important pathogen-specific infections and their relative frequency. Recent literature is summarized that has helped elucidate the pathophysiologic basis for their occurrence. Finally, evolving sets of recommendations for prevention, diagnosis, and treatment of infectious complications of their use are explored. RECENT FINDINGS: Tuberculosis has continued to be the most common pathogen reported in association with infliximab, and less so with etanercept and adalimumab. Determining treated population case rates depends on having an accurate denominator and reflects the local population's latent infection rate. The same is true for histoplasmosis. Other pathogens requiring intact cellular immunity for control of latent infection have also been reported. Specific recommendations for preventive therapy are being made, but prospective clinical trials are needed to assess the risk-benefit of any particular approach. SUMMARY: Microorganisms responsible for the infectious complications associated with anticytokine therapy are generally intracellular pathogens or pathogens that commonly exist in a chronic, latent state and are normally held in check by cell-mediated immunity. Diagnosis requires a high index of suspicion and prompt acquisition of appropriate tissue for microscopic examination and microbiologic culture. Prompt empiric therapy that focuses on the most likely infections is necessary to prevent mortality.
Biological Therapy↗
Tuberculosis in the cytokine era: what rheumatologists need to know.
Explore the source record for details and available documents.
Antirheumatic Agents↗
Reactivation of retinal toxoplasmosis despite evidence of immune response to highly active antiretroviral therapy.
We report a case of retinal toxoplasmosis that occurred in a patient with acquired immunodeficiency syndrome who had a previous diagnosis of cerebral toxoplasmosis, despite the patient having had a robust immune response to highly active antiretroviral therapy. Clinical decisions about whether to discontinue secondary prophylaxis for opportunistic infections continue to be challenging.
AIDS-Related Opportunistic Infections↗
Epidemiology of human immunodeficiency virus testing among patients with tuberculosis in North Carolina.
BACKGROUND: Human immunodeficiency virus (HIV) testing is recommended for all patients with tuberculosis (TB). METHODS: Surveillance data for all reported cases of TB in North Carolina from 1993 to 1999 were examined to assess HIV testing practices. RESULTS: Of 3,680 TB patients, 3,119 (85%) had HIV testing data reported. Of these, 604 (19%) were not offered HIV testing, 465 (18%) refused testing, 379 (15%) were HIV seropositive, 29 (0.8%) were tested but results were not reported, and 1 (0.03%) had an indeterminate result. Older patients were significantly less likely to be offered HIV testing and more likely to refuse testing. Males and African Americans were more likely to be offered and to accept testing. CONCLUSIONS: At least 34% of TB patients in North Carolina from 1993 to 1999 did not receive HIV testing. Patients in higher-risk groups were more likely to be tested, but even within the highest-risk groups, testing was not universal. Health care providers should offer HIV testing to all individuals with TB.
AIDS Serodiagnosis↗